What he's saying is that drugs are marked up more in the US than other countries that regulate their prices. That necessarily implies that Americans paying for the drug are contributing more to pharma revenues than those in countries that are regulating prescription drug prices.
But that's not necessarily true, and the statement was regarding R&D not general income. The larger income in America part can also be questioned, particularly when the revenue in the US comes also comes a large cost of marketing - which some reports say exceed the cost of R&D. The US is also one of the few nations that allows that expenditure. It seems like we're just paying to much and funding a lot of marketing and doing nothing for R&D of drugs.
